What question did this study set out to answer?

To provide practical guidance for integrating cardio-oncology guidelines into oncology practice for managing cardiac dysfunction related to cancer therapy.

March 29, 2026Open Access

Standardizing the Clinical Approach to Cancer Therapy‐Related Cardiac Dysfunction: Applying Cardio‐Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers

Key Result

A case-based cardio-oncology framework equips oncology providers to perform baseline cardiovascular risk stratification, surveillance, and management of therapy-related cardiac dysfunction.

Key Points

To provide practical guidance for integrating cardio-oncology guidelines into oncology practice for managing cardiac dysfunction related to cancer therapy.
Developed by a multidisciplinary panel of experts.
Presented clinical scenarios demonstrating real-world challenges.
Applied evidence-based recommendations from leading cardio-oncology guidelines.
Focused on cardiovascular risk stratification before treatment initiation.
Outlined strategies for monitoring and managing heart failure in cancer patients.
Highlighted inconsistencies in the application of existing guidelines in practice.
Emphasized importance of individualized surveillance strategies for high-risk patients.
Provided a structured framework for early detection and management of CTRCD.
Encouraged adherence to guideline-directed medical therapy to reduce cardiovascular risk.

Structured PICO

Population

Cancer patients at risk of or with cancer therapy-related cardiac dysfunction (CTRCD)

Intervention

Application of cardio-oncology guidelines (ESC and ICOS)

This consensus statement provides a practical, case-based framework to help oncology providers implement cardio-oncology guidelines for managing cancer therapy-related cardiac dysfunction.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

ABSTRACT Introduction and Methods Cancer therapy–related cardiac dysfunction (CTRCD) is a well established and potentially life‐threatening complication of contemporary oncologic treatment. Although comprehensive cardio‐oncology guidelines have been developed, their integration into routine hematology and oncology practice remains inconsistent. This consensus statement, developed by a multidisciplinary panel of cardio‐oncology experts, aims to provide practical, case‐based guidance to help oncology providers recognize, assess, and manage CTRCD across a spectrum of malignancies and cardiovascular presentations. Clinical Scenarios and Discussion We present representative clinical scenarios that illustrate real‐world challenges in cardio‐oncology and apply evidence‐based recommendations from current guidelines, including those from the European Society of Cardiology (ESC) and the International Cardio‐Oncology Society (ICOS)—to support informed decision‐making. Key areas of focus include baseline cardiovascular risk stratification prior to initiating potentially cardiotoxic therapies, with an emphasis on biomarker and imaging surveillance strategies tailored to individual risk profiles. Also, this document outlines the application of guideline‐directed medical therapy (GDMT) for cancer patients with heart failure. Conclusion By offering a structured, user‐friendly framework, this document seeks to bridge the implementation gap between oncology and cardiology disciplines. Our goal is to equip oncology providers with accessible tools that facilitate early recognition, consistent surveillance, and timely referral, thereby preserving cancer treatment intensity while minimizing cardiovascular morbidity.